Clinical trials: Tolerance of the Liver
Hepatocellular Carcinoma
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Trial name
- NCT02314052
- Testing
- DCR-MYC
- Where
- 6 sites in United States, Singapore and 1 more
- Volunteers
- 21 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Liver Disease, Liver Transplantation
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected.
- Trial name
- TILT (NCT00105235)
- Testing
- Alemtuzumab, Cyclosporine, Mycophenolate mofetil
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant, Liver Transplantation
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
The primary aim of this study is to determine whether a peripheral blood or graft lymphocyte phenotype of immune senescence or exhaustion is different between operationally tolerant and non-tolerant liver allograft recipients.
- Trial name
- OPTIMAL (NCT02533180)
- Testing
- Immunosuppression withdrawal
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)